Venture Investing | Shaping GCT Translation - 2021 World Medical Innovation Forum
May 2–4, 2022

Venture Investing | Shaping GCT Translation

Venture Investing | Shaping GCT Translation

Friday, May 21, 2021

8:30 AM – 8:55 AM

What is occurring in the GCT venture capital segment? Which elements are seeing the most activity? Which areas have cooled? How is the investment market segmented between gene therapy, cell therapy and gene editing? What makes a hot GCT company? How long will the market stay frothy? Some review of demographics — # of investments, sizes, etc. Why is the market hot and how long do we expect it to stay that way? Rank the top 5 geographic markets for GCT company creation and investing? Are there academic centers that have been especially adept at accelerating GCT outcomes? Do the business models for the rapid development of coronavirus vaccine have any lessons for how GCT technology can be brought to market more quickly?

Meredith Fisher, PhD
  • Partner, Mass General Brigham Ventures
David Berry, MD, PhD
  • CEO, Valo Health
  • General Partner, Flagship Pioneering
Robert Nelsen
  • Managing Director, Co-founder, ARCH Venture Partners
Kush Parmar, MD, PhD
  • Managing Partner, 5AM Ventures
  • Q&A

    09:00 AM – 09:15 AM

the Future of Medicine and AI

May 11–13, 2020 | Boston, MA